Bispecific Antibody-directed Antitumor Activity of Human CD4+Helper/Killer T Cells Induced by Anti-CD3 Monoclonal Antibody plus Interleukin 2
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.1991.tb01782.x/fullpdf
Reference20 articles.
1. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells;North;J. Exp. Med.,1982
2. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2;Nishimura;Cancer Immunol. Immunother.,1986
3. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2;Cheever;J. Exp. Med.,1982
4. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumors by interleukin 2 activated autologous human peripheral blood lymphocytes. J;Grimm;Exp. Med.,1982
5. Generation of lyrriphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes;Nishimura;Cell. Immunol,1986
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies;BMC Cancer;2013-02-22
2. Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery;Current Drug Delivery;2012-03-01
3. Tumor-specific targeting of T helper type 1 (Th1) cells by anti-CD3 × anti-c-ErbB-2 bispecific antibody;Cancer Immunology, Immunotherapy;1999-10-15
4. Activated CD4+ T cells preferentially take up lipid microspheres, but resting cells do not;Clinical and Experimental Immunology;1995-03
5. Production and In Vivo Characterization of a Bifunctional Antibody (IVA039.1) with Specificity for the Mouse Interleukin-2 Receptor and Vinca Alkaloids;Hybridoma;1994-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3